Phase 2 study of BGB-45035
Latest Information Update: 14 May 2025
At a glance
- Drugs BGB 45035 (Primary)
- Indications Autoimmune disorders
- Focus Proof of concept; Therapeutic Use
Most Recent Events
- 07 May 2025 According to BeiGene media release, first patient enrollment and proof-of-concept data for tissue IRAK4 degradation are planned in 2H2025.
- 03 Mar 2025 New trial record
- 27 Feb 2025 According to BeiGene media release, Phase 2 study is planned in second half of 2025.